Shattuck Labs Joins Russell 2000 and 3000 Indexes

Shattuck Labs, Inc., a clinical-stage biotechnology firm based in Austin, Texas, and Durham, North Carolina, has announced its inclusion in the Russell 2000® and Russell 3000® Indexes following the 2024 Russell U.S. Indexes annual reconstitution. This incorporation will take effect as the U.S. equity markets open today.

Andrew R. Neill, the Chief Financial Officer of Shattuck, expressed his satisfaction with this development, highlighting the company's progress in 2024. Specifically, Neill mentioned the rapid advancement of their lead program, SL-172154, particularly in high-risk myelodysplastic syndromes (HR-MDS) and TP53-mutant acute myeloid leukemia (TP53m AML). The company is pushing SL-172154 forward in these areas as they are believed to offer the fastest route to approval. Neill also indicated that Shattuck looks forward to providing further updates from ongoing clinical trials.

The Russell U.S. Indexes reconstitution is an annual event that ranks the 4,000 largest U.S. stocks by total market capitalization as of April 30. Being part of the all-cap Russell 3000® Index ensures automatic inclusion in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, along with relevant growth and value style indexes. FTSE Russell, the body responsible for these indexes, primarily bases membership on objective market-capitalization rankings and style attributes. These indexes are widely utilized by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

Shattuck Labs focuses on developing bi-functional fusion proteins, a new class of biologic medicine aimed at treating cancer and autoimmune diseases. Their proprietary ARC® platform generates compounds designed to both inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s leading candidate, SL-172154 (SIRPα-Fc-CD40L), is under evaluation in several Phase 1 trials. This compound aims to block the CD47 immune checkpoint while concurrently activating the CD40 pathway.

Headquartered in both Austin, Texas, and Durham, North Carolina, Shattuck Labs is positioning itself at the forefront of innovative treatments in oncology and autoimmune diseases. The company's inclusion in the Russell Indexes is a significant milestone that underscores its recent advancements and the potential of its clinical programs.

FTSE Russell is acknowledged as a leading global provider of benchmarking, analytics, and data solutions for investors. Their comprehensive range of precise and reliable indexes assists investors worldwide in measuring and benchmarking markets across various asset classes, styles, and strategies. The firm's index expertise is extensively utilized by both institutional and retail investors globally. Over the past 30 years, top asset owners, managers, ETF providers, and investment banks have chosen FTSE Russell indexes for benchmarking investment performance and creating index-based products.

FTSE Russell operates under the highest industry standards in index design and governance, applying a transparent, rules-based methodology informed by independent committees of leading market participants. The organization is wholly owned by the London Stock Exchange Group and remains committed to innovation driven by client needs and customer partnerships, continually enhancing the range and depth of its offerings.